Lupeng Pharmaceutical Ltd.

麓鹏制药有限公司

Develops LP-168, a dual-mechanism (covalent and non-covalent) BTK inhibitor for blood cancers including DLBCL, MCL and CLL/SLL, at NDA stage with clinical trials in the US and China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Reliance on platforms, partners or licences
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Net current liabilities or net liabilities
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Related-party transactions and balances
• Chapter 18A biotech